Zentiva calls meeting on Sanofi bid

Czech drugmaker Zentiva has called a special shareholders meeting Sept. 3 to consider Sanofi-Aventis' buyout offer--and to consider competing bids. Last month, Zentiva management told shareholders to reject the $1.86 billion bid because it didn't adequately reflect the company's value. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.